Q2 EPS Forecast for Aprea Therapeutics Lifted by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Aprea Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.22) per share for the quarter, up from their previous forecast of ($0.24). The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.22) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($1.05) EPS.

Other equities analysts have also recently issued reports about the stock. Oppenheimer started coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Finally, Wedbush reduced their price target on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.07.

Aprea Therapeutics Stock Up 2.5%

APRE opened at $0.66 on Wednesday. The stock has a market capitalization of $8.17 million, a price-to-earnings ratio of -0.43 and a beta of 1.52. Aprea Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.79. The company has a 50-day simple moving average of $0.71 and a 200 day simple moving average of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.

Hedge Funds Weigh In On Aprea Therapeutics

A number of hedge funds have recently made changes to their positions in APRE. Jane Street Group LLC bought a new stake in Aprea Therapeutics in the fourth quarter valued at approximately $40,000. DRW Securities LLC bought a new position in Aprea Therapeutics during the 4th quarter worth approximately $103,000. Finally, AIGH Capital Management LLC raised its holdings in Aprea Therapeutics by 174.1% during the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after purchasing an additional 645,000 shares during the last quarter. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.